Loading...
•
Mar 31, 2024
Zentalis Q1 2024 Earnings Report
Reported financial results for the first quarter of 2024 and highlighted recent corporate accomplishments.
Key Takeaways
Zentalis Pharmaceuticals reported its Q1 2024 financial results, highlighting a cash, cash equivalents, and marketable securities position of $489.0 million. The company anticipates a catalyst-rich period in the second half of 2024 and into 2025, focusing on the clinical profile of azenosertib.
Azenosertib clinical development plan remains on track with multiple data readouts anticipated in the second half of 2024 and into 2025.
Final results from Phase 1 study of azenosertib in combination with gemcitabine in adult and pediatric patients with relapsed or refractory osteosarcoma to be presented at the 2024 ASCO Annual Meeting.
Preclinical data presented at AACR demonstrated synergistic anti-tumor activity of azenosertib with KRASG12C inhibitors.
Cash runway is projected into mid-2026.
Zentalis
Zentalis
Forward Guidance
Zentalis anticipates multiple data readouts in gynecological and other cancer types in the second half of 2024 and into 2025. The company expects topline data from several Phase 1/2 and Phase 2 studies, including those for azenosertib in platinum resistant ovarian cancer and recurrent or persistent USC.
Positive Outlook
- Presentation of final results of Phase 1 azenosertib + chemotherapy trial in R/R osteosarcoma at 2024 ASCO Annual Meeting
- Presentation of final results of Phase 1b azenosertib monotherapy trial in solid tumors
- Topline data from Phase 1/2 MAMMOTH azenosertib + PARP inhibitor trial in platinum resistant ovarian cancer
- Presentation of initial data from Phase 1 azenosertib + BEACON regimen trial in BRAF mutant metastatic colorectal cancer
- Initial data from Phase 1 azenosertib + ZN-d5 trial in R/R AML